Search results for "Glycemic"

showing 10 items of 331 documents

Evaluation of CGMS® During Rapid Blood Glucose Changes in Patients with Type 1 Diabetes

2006

CGMS (Medtronic Minimed, Duesseldorf, Germany) allows continuous glucose monitoring. Recent studies with invasive monitoring techniques revealed discrepancies in blood glucose measurements obtained from different anatomical sites compared with those from the fingertip. The aim of this study was to investigate the CGMS and a device for alternative site testing (AST) during dynamic blood glucose changes and to compare these results with fingertip measurements.Twelve patients with type 1 diabetes (seven women, five men; age, 33.3 +/- 8.7 years) received a 75-g oral glucose load. Insulin was applied intravenously (rapid glucose decline) or subcutaneously (moderate glucose decline) in a dosage b…

AdultBlood GlucoseMalemedicine.medical_specialtyInjections SubcutaneousEndocrinology Diabetes and Metabolismmedicine.medical_treatmentEndocrinologyForearmDiabetes mellitusmedicineHumansHypoglycemic AgentsInsulinIn patientBlood Glucose MeasurementType 1 diabetesbusiness.industryBlood Glucose Self-MonitoringSite testingInsulinGlucose MeasurementMiddle Agedmedicine.diseaseSurgeryMedical Laboratory TechnologyDiabetes Mellitus Type 1medicine.anatomical_structureAnesthesiaInjections IntravenousFemalebusinessDiabetes Technology & Therapeutics
researchProduct

Resting Energy expenditure in type 2 diabetic patients and the effect of insulin bolus

2014

Aims: Resting energy expenditure (REE) plays a critical role in the regulation of body weight, with important implications in type 2 diabetes (T2D). However, the relationships between REE and T2D have not been extensively evaluated. We compared REE in persons with diabetes and in persons without diabetes. We also investigated the acute effect of insulin on REE and venous lactate, the latter an indirect measure of neoglucogenetic activity. Methods: REE was measured using indirect calorimetry in 14 newly diagnosed, untreated T2D adults and in 14 non-diabetic age-, gender- and body mass index-matched persons. The REE and lactate venous concentrations were also measured in a subgroup of 5 T2D p…

AdultBlood GlucoseMalemedicine.medical_specialtyRestEndocrinology Diabetes and Metabolismmedicine.medical_treatmentType 2 diabetesBody weightBody Mass IndexSettore MED/13 - EndocrinologiaEndocrinologyBolus (medicine)Internal medicineDiabetes mellitusInternal MedicinemedicineHumansHypoglycemic AgentsInsulinResting energy expenditureSettore MED/49 - Scienze Tecniche Dietetiche ApplicateAgedbusiness.industryInsulinBody WeightCalorimetry IndirectGeneral MedicinePlasma glucose concentrationMiddle Agedmedicine.diseasediabetes insulin lactate neoglucogenesis resting energy expenditure indirect calorimetryEndocrinologyDiabetes Mellitus Type 2GluconeogenesisFemaleEnergy IntakeEnergy MetabolismbusinessFollow-Up Studies
researchProduct

Professional continuous glucose monitoring in subjects with type 1 diabetes: retrospective hypoglycemia detection.

2013

Background: An important task in diabetes management is detection of hypoglycemia. Professional continuous glucose monitoring (CGM), which produces a glucose reading every 5 min, is a powerful tool for retrospective identification of unrecognized hypoglycemia. Unfortunately, CGM devices tend to be inaccurate, especially in the hypoglycemic range, which limits their applicability for hypoglycemia detection. The objective of this study was to develop an automated pattern recognition algorithm to detect hypoglycemic events in retrospective, professional CGM. Method: Continuous glucose monitoring and plasma glucose (PG) readings were obtained from 17 data sets of 10 type 1 diabetes patients und…

AdultBlood GlucoseMalemedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and MetabolismBiomedical EngineeringBioengineeringHypoglycemiaSensitivity and SpecificityAutomationDiabetes managementBlood Glucose Self-MonitoringDiabetes mellitusInternal MedicineMedicineHumansIntensive care medicineGlycemicMonitoring PhysiologicRetrospective StudiesType 1 diabetesbusiness.industryContinuous glucose monitoringBlood Glucose Self-Monitoringnutritional and metabolic diseasesRetrospective cohort studyMiddle Agedmedicine.diseaseHypoglycemiaDiabetes Mellitus Type 1Original ArticlebusinessAlgorithmsJournal of diabetes science and technology
researchProduct

Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers.

2003

Pharmacokinetic and pharmacodynamic profiles of the rapid-acting insulin analogues lispro and aspart were compared in a randomized, double-blind crossover study of 20 fasting healthy men following a single subcutaneous injection. Either insulin lispro or aspart, 0.05 U/kg-body-weight, was injected subcutaneously and followed by determination of 5-h profiles of plasma glucose, serum C-peptide and insulin concentrations. Lowest glucose concentrations were observed after 50 min in the aspart group (3.2 +/- 0.1 mmol/l versus lispro 3.5 +/- 0.1 mmol/l; p = 0.026) and after 60 min in the lispro group (3.4 +/- 0.1 mmol/l). For blood glucose t min was 59.3 +/- 3.4 min in the aspart and 63.5 +/- 5.3…

AdultBlood GlucoseMalemedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentRadioimmunoassayInsulin aspartSubcutaneous injectionEndocrinologyPharmacokineticsDouble-Blind MethodDiabetes mellitusInternal medicineInternal MedicinemedicineInsulin lisproHumansHypoglycemic AgentsInsulinInsulin AspartCross-Over StudiesInsulin LisproC-Peptidebusiness.industryInsulindigestive oral and skin physiologynutritional and metabolic diseasesGeneral Medicinemedicine.diseaseCrossover studyEndocrinologyPharmacodynamicsbusinesshormones hormone substitutes and hormone antagonistsmedicine.drugExperimental and clinical endocrinologydiabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
researchProduct

Early administration of an immunomodulator and induction of remission in insulin-dependent diabetes mellitus

1990

A clinical trial was undertaken to determine whether intensive thymopentin administration enhances remission of insulin-dependent diabetes (IDDM) during the first year after diagnosis. Dosage with insulin was minimized with target control of blood glucose levels less than or equal to 7.8 mmol/l before meals. Remission was defined as a prolonged period after IDDM onset (not less than 3 months) characterized by a non-insulin-receiving (NIR) state in which target metabolic control was reached without administration of insulin and with a valid C-peptide response, evaluated after standard breakfast. Sixteen IDDM patients aged 12-31 years, recruited within 2 weeks of initiation of insulin therapy…

AdultBlood Glucosemedicine.medical_specialtyAdolescentmedicine.medical_treatmentImmunologyGastroenterologyInternal medicineDiabetes mellitusmedicineHumansInsulinImmunology and AllergyThymopentinChildGlycemicImmunity CellularC-Peptidebusiness.industryInsulinRemission InductionHemoglobin AReceptors Interleukin-2medicine.diseaseClinical trialTiterDiabetes Mellitus Type 1EndocrinologyChild PreschoolInsulin dependent diabetesMetabolic control analysisThymopentinbusinessmedicine.drugJournal of Autoimmunity
researchProduct

Use of glargine in pregnant women with type 1 diabetes mellitus: a case-control study.

2008

BACKGROUND: Insulin glargine is a once-daily basal insulin analog with prolonged duration of action and absence of an evident peak. Glargine is associated with reduced frequency of hypoglycemic episodes (mostly nocturnal) as well as effective glycemic control. Maintenance of good metabolic control before conception and throughout pregnancy is essential to lower the risk of fetal malformations. Glargine might be a valuable alternative in the management of pregnancies complicated by diabetes mellitus. However, because its clinical utility has not been established, the use of glargine is not currently recommended during pregnancy. OBJECTIVE: The aim of this study was to retrospectively evaluat…

AdultBlood Glucosemedicine.medical_specialtyInsulin IsophanePregnancy in DiabeticsInsulin GlargineSettore MED/13 - EndocrinologiaInsulin aspartPregnancyDiabetes mellitusInternal medicinemedicineOutpatient clinicInsulin lisproHumansHypoglycemic AgentsInsulinPharmacology (medical)Body Weights and MeasuresFemurInsulin AspartGlycemicRetrospective StudiesPharmacologyGlycated HemoglobinType 1 diabetesPregnancyInsulin LisproInsulin glarginebusiness.industryglargine type 1 diabetesPregnancy Outcomemedicine.diseaseInsulin Long-ActingEndocrinologyDiabetes Mellitus Type 1Case-Control StudiesFemalebusinessmedicine.drugClinical therapeutics
researchProduct

Pharmacotherapy for gestational diabetes mellitus: still insulin, or what about sulfonylureas?

2018

Randomized trials have not focused on neonatal complications of glyburide for women with gestational diabetes.To compare oral glyburide vs subcutaneous insulin in prevention of perinatal complications in newborns of women with gestational diabetes.The Insulin Daonil trial (INDAO), a multicenter noninferiority randomized trial conducted between May 2012 and November 2016 (end of participant follow-up) in 13 tertiary care university hospitals in France including 914 women with singleton pregnancies and gestational diabetes diagnosed between 24 and 34 weeks of gestation.Women who required pharmacologic treatment after 10 days of dietary intervention were randomly assigned to receive glyburide …

AdultBlood Glucosemedicine.medical_specialtyendocrine system diseasesInjections Subcutaneousmedicine.medical_treatmentAdministration Oral030209 endocrinology & metabolism.OverweightInfant Newborn DiseasesFetal Macrosomia03 medical and health sciences0302 clinical medicinePharmacotherapyInsulin resistancePregnancyInternal medicineGlyburidemedicineHumansHypoglycemic AgentsInsulin030212 general & internal medicineFamily historyHyperbilirubinemiabusiness.industryInsulinInfant NewbornPregnancy Outcomenutritional and metabolic diseasesType 2 Diabetes MellitusGeneral Medicinemedicine.diseaseHypoglycemiafemale genital diseases and pregnancy complicationsGestational diabetesDiabetes GestationalEditorialEndocrinologyFemalemedicine.symptomMetabolic syndromebusinessAnnals of Translational Medicine
researchProduct

Definition of the upper reference limit of glycated albumin in blood donors from Italy.

2017

Abstract Background: Glycated Albumin (GA) has been proposed as a short-term indicator of glycemic homeostasis. The aim of this study is to describe the distribution of GA in a large sample of blood donors from Italy to evaluate whether demographic features, namely age and sex, could influence GA levels and define specific reference limits. Methods: The study included 1334 Italian blood donors. GA was measured using an enzymatic method (quantILab Glycated Albumin, IL Werfen, Germany). The upper reference limit (URL) was calculated using the non-parametric percentile method. Results: A modest, although significant, increase of GA was observed in relation to age (p<0.001), especially in ma…

AdultGlycation End Products AdvancedMalemedicine.medical_specialtyPercentileAdolescentClinical BiochemistryPopulationSerum albuminEnzyme Assay030209 endocrinology & metabolismBlood Donors030204 cardiovascular system & hematology03 medical and health sciencesYoung Adult0302 clinical medicineGlycated albuminReference ValuesInternal medicineDiabetes mellitusmedicineblood donors; diabetes; glycated albumin; reference limit; Adolescent; Adult; Aged; Enzyme Assays; Female; Humans; Italy; Male; Middle Aged; Reference Values; Serum Albumin; Young Adult; Blood Donors; Clinical Biochemistry; Biochemistry (medical)HumansReference ValueGlycated Serum AlbuminYoung adulteducationSerum AlbuminGlycemicAgedEnzyme Assayseducation.field_of_studydiabetesbiologyBlood Donorbusiness.industryBiochemistry (medical)General MedicineMiddle Agedreference limitmedicine.diseaseLarge sampleItalydiabetebiology.proteinglycated albuminFemalebusinessHumanClinical chemistry and laboratory medicine
researchProduct

Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

2022

AbstractThe STEP 5 trial assessed the efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg versus placebo (both plus behavioral intervention) for long-term treatment of adults with obesity, or overweight with at least one weight-related comorbidity, without diabetes. The co-primary endpoints were the percentage change in body weight and achievement of weight loss of ≥5% at week 104. Efficacy was assessed among all randomized participants regardless of treatment discontinuation or rescue intervention. From 5 October 2018 to 1 February 2019, 304 participants were randomly assigned to semaglutide 2.4 mg (n = 152) or placebo (n = 152), 92.8% of whom completed the trial (attended t…

AdultMaleGlucagon-Like PeptideHypoglycemic AgentObesidadInvestigación médicaGeneral MedicineMiddle AgedOverweightWeight LoGeneral Biochemistry Genetics and Molecular BiologyTratamiento médicoTreatment OutcomeDouble-Blind MethodDiabetes Mellitus Type 2GlucemiaControl glucémicoFemaleObesitySettore MED/49 - Scienze Tecniche Dietetiche ApplicateHuman
researchProduct

Potato consumption does not increase blood pressure or incident hypertension in 2 cohorts of Spanish adults

2017

5 Tablas

AdultMalePediatricsmedicine.medical_specialtyDiastoleMedicine (miscellaneous)030204 cardiovascular system & hematologyMediterranean03 medical and health sciences0302 clinical medicineAnimal scienceGlycemic loadSUN cohortmedicineHumans030212 general & internal medicineIntervention trialProspective cohort studyPotatoesGeneralized estimating equationAgedSolanum tuberosumAged 80 and overNutrition and DieteticsIncrease blood pressurebusiness.industryIncidence (epidemiology)PREDIMED studyMiddle AgedDietBlood pressureSpainHypertensionBlood pressureFemalebusiness
researchProduct